{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:01:30Z","timestamp":1787032890765,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,24]]},"DOI":"10.7759\/cureus.82940","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T21:36:12Z","timestamp":1745530572000},"source":"Crossref","is-referenced-by-count":2,"title":["Pembrolizumab-Induced Hypophysitis in the Setting of Renal Cell Carcinoma"],"prefix":"10.7759","author":[{"given":"Kassandra","family":"Ogbodu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukul","family":"Sharda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naisarg B","family":"Vanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinky","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000037587","article-title":"The association of hypophysitis with immune checkpoint inhibitors use: gaining insight through the FDA pharmacovigilance database","volume":"103","author":"Tang Q","year":"2024","unstructured":"Tang Q, Han Y, Song M, Peng J, Zhang M, Ren X, Sun H. The association of hypophysitis with immune checkpoint inhibitors use: gaining insight through the FDA pharmacovigilance database. Medicine (Baltimore). 2024, 103:e37587. 10.1097\/MD.0000000000037587","journal-title":"Medicine (Baltimore)"},{"key":"ref2","article-title":"Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline","volume":"101","author":"Bornstein SR","year":"2016","unstructured":"Bornstein SR, Allolio B, Arlt W, Barthel A. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society clinical practice guideline. \u200bJ Clin Endocrinol Metab\u200b. 2016, 101:364-89.","journal-title":"\u200bJ Clin Endocrinol Metab\u200b"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.27763","article-title":"Exploring a new entity of single-agent pembrolizumab-associated hypophysitis","volume":"14","author":"Balti E","year":"2022","unstructured":"Balti E, Verhaeghe S, Kruse V, Roels S, Coremans P. Exploring a new entity of single-agent pembrolizumab-associated hypophysitis. Cureus. 2022, 14:e27763. 10.7759\/cureus.27763","journal-title":"Cureus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain L","year":"2016","unstructured":"Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016, 44:51-60. 10.1016\/j.ctrv.2016.02.001","journal-title":"Cancer Treat Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi M","year":"2022","unstructured":"Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022, 21:28. 10.1186\/s12943-021-01489-2","journal-title":"Mol Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins F","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, et al.. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019, 16:563-80. 10.1038\/s41571-019-0218-0","journal-title":"Nat Rev Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","author":"Ryder M","year":"2014","unstructured":"Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014, 21:371-81. 10.1530\/ERC-13-0499","journal-title":"Endocr Relat Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31200","article-title":"Endocrine dysfunction induced by immune checkpoint inhibitors: practical recommendations for diagnosis and clinical management","volume":"124","author":"Barroso-Sousa R","year":"2018","unstructured":"Barroso-Sousa R, Ott PA, Hodi FS, Kaiser UB, Tolaney SM, Min L. Endocrine dysfunction induced by immune checkpoint inhibitors: practical recommendations for diagnosis and clinical management. Cancer. 2018, 124:1111-21. 10.1002\/cncr.31200","journal-title":"Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.505","article-title":"Immune checkpoint inhibitors-induced endocrinopathies: assessment, management, and monitoring in a comprehensive cancer center","volume":"7","author":"Elshafie O","year":"2024","unstructured":"Elshafie O, Khalil AB, Salman B, Atabani A, Al-Sayegh H. Immune checkpoint inhibitors-induced endocrinopathies: assessment, management, and monitoring in a comprehensive cancer center. Endocrinol Diabetes Metab. 2024, 7:e00505. 10.1002\/edm2.505","journal-title":"Endocrinol Diabetes Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1159\/000491631","article-title":"Acute kidney injury after pembrolizumab-induced adrenalitis and adrenal insufficiency","volume":"8","author":"Hanna RM","year":"2018","unstructured":"Hanna RM, Selamet U, Bui P, et al.. Acute kidney injury after pembrolizumab-induced adrenalitis and adrenal insufficiency. Case Rep Nephrol Dial. 2018, 8:171-7. 10.1159\/000491631","journal-title":"Case Rep Nephrol Dial"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcr\/yty038","article-title":"Cardiac tamponade and adrenal insufficiency due to pembrolizumab: a case report","volume":"2","author":"Oristrell G","year":"2018","unstructured":"Oristrell G, Ba\u00f1eras J, Ros J, Mu\u00f1oz E. Cardiac tamponade and adrenal insufficiency due to pembrolizumab: a case report. Eur Heart J Case Rep. 2018, 2:yty038. 10.1093\/ehjcr\/yty038","journal-title":"Eur Heart J Case Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4158\/ACCR-2019-0585","article-title":"A common pituitary autoantibody in two patients with immune checkpoint inhibitor-mediated hypophysitis: ZCCHC8","volume":"6","author":"Leiter A","year":"2020","unstructured":"Leiter A, Gnjatic S, Fowkes M, Kim-Schulze S, Laface I, Galsky MD, Gallagher EJ. A common pituitary autoantibody in two patients with immune checkpoint inhibitor-mediated hypophysitis: ZCCHC8. AACE Clin Case Rep. 2020, 6:e151-60. 10.4158\/ACCR-2019-0585","journal-title":"AACE Clin Case Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0061","article-title":"Clinical course and management of pembrolizumab-associated isolated adrenocorticotrophic hormone deficiency: a new case and literature review","volume":"13","author":"O\u011fuz SH","year":"2021","unstructured":"O\u011fuz SH, \u00dcnl\u00fct\u00fcrk U, Aksoy S, Erbas T. Clinical course and management of pembrolizumab-associated isolated adrenocorticotrophic hormone deficiency: a new case and literature review. Immunotherapy. 2021, 13:1157-63. 10.2217\/imt-2021-0061","journal-title":"Immunotherapy"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luae200","article-title":"Pembrolizumab-induced thyroiditis, hypophysitis and adrenalitis: a case of triple endocrine dysfunction","volume":"2","author":"Rossi S","year":"2024","unstructured":"Rossi S, Silvetti F, Bordoni M, Ciarloni A, Salvio G, Balercia G. Pembrolizumab-induced thyroiditis, hypophysitis and adrenalitis: a case of triple endocrine dysfunction. JCEM Case Rep. 2024, 2:luae200. 10.1210\/jcemcr\/luae200","journal-title":"JCEM Case Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10. 10.1186\/s40780-024-00332-2","article-title":"Pembrolizumab-induced secondary adrenal insufficiency due to adrenocorticotrophic hormone deficiency in a patient with non-small-cell lung carcinoma: a case report","volume":"16","author":"Fujimiya T","year":"2024","unstructured":"Fujimiya T, Azuma K, Togashi Y, Kuwata K, Unezaki S, Takeuchi H. Pembrolizumab-induced secondary adrenal insufficiency due to adrenocorticotrophic hormone deficiency in a patient with non-small-cell lung carcinoma: a case report. J Pharm Health Care Sci. 2024, 16:10. 10. 10.1186\/s40780-024-00332-2","journal-title":"J Pharm Health Care Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15465","article-title":"Pembrolizumab-induced hypophysitis with isolated adrenocorticotropic hormone (ACTH) deficiency: a rare immune-mediated adverse event","volume":"13","author":"Doodnauth AV","year":"2021","unstructured":"Doodnauth AV, Klar M, Mulatu YS, Malik ZR, Patel KH, McFarlane SI. Pembrolizumab-induced hypophysitis with isolated adrenocorticotropic hormone (ACTH) deficiency: a rare immune-mediated adverse event. Cureus. 2021, 13:e15465. 10.7759\/cureus.15465","journal-title":"Cureus"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001129","article-title":"Hypophysitis secondary to pembrolizumab: a case report and review of the literature","volume":"33","author":"Montero P\u00e9rez O","year":"2022","unstructured":"Montero P\u00e9rez O, S\u00e1nchez Escudero L, Guzm\u00e1n Ramos MI, Avi\u00f1\u00f3 Tarazona V. Hypophysitis secondary to pembrolizumab: a case report and review of the literature. Anticancer Drugs. 2022, 33:94-9. 10.1097\/CAD.0000000000001129","journal-title":"Anticancer Drugs"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.55729\/2000-9666.1173","article-title":"Pembrolizumab-induced broken heart syndrome, pneumonitis, and hypophysitis occurring concurrently; a deadly triad","volume":"13","author":"Khan WJ","year":"2023","unstructured":"Khan WJ, Asif M, Chaudhry HS, Aslam S, Nadeem I. Pembrolizumab-induced broken heart syndrome, pneumonitis, and hypophysitis occurring concurrently; a deadly triad. J Community Hosp Intern Med Perspect. 2023, 13:88-90. 10.55729\/2000-9666.1173","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luad135","article-title":"Nothing great comes without its risks: a rare case of pembrolizumab-induced hypophysitis","volume":"2","author":"Fernando A","year":"2024","unstructured":"Fernando A, Mittal A, Cheema R. Nothing great comes without its risks: a rare case of pembrolizumab-induced hypophysitis. JCEM Case Rep. 2024, 2:135. 10.1210\/jcemcr\/luad135","journal-title":"JCEM Case Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2023.14199","article-title":"Hypopituitarism induced by pembrolizumab plus axitinib in the treatment of metastatic renal cell carcinoma: a case report","volume":"27","author":"Hanawa K","year":"2024","unstructured":"Hanawa K, Sawada N, Aikawa J, et al.. Hypopituitarism induced by pembrolizumab plus axitinib in the treatment of metastatic renal cell carcinoma: a case report. Oncol Lett. 2024, 27:66. 10.3892\/ol.2023.14199","journal-title":"Oncol Lett"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/349314-pembrolizumab-induced-hypophysitis-in-the-setting-of-renal-cell-carcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T21:36:13Z","timestamp":1745530573000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/349314-pembrolizumab-induced-hypophysitis-in-the-setting-of-renal-cell-carcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.82940","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,24]]}}}